COMP <GO>
PFE vs ABBV // OPERATING MARGIN
Pfizer Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PFE 6
— ABBV 8
▲ OPERATING MARGIN LEADER: ABBV
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
operating-margins
15.10%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
operating-margins
24.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 70.20% | +4.10 | PFE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 29.00% | -23.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 33.3x | -13.60 | PFE | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 3.47% | +1.85 | PFE | /fcf-yield <GO> |
| Operating Margin ACTIVE | 15.10% | 24.60% | -9.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 6.90% | +5.50 | PFE | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 8.60% | -10.20 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 5.33 | -3.23 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | PFE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.5 | 72.8 | -6.24 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.15 | -0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 113.1x | -92.60 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $513.86B | -$343.15B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | ABBV REV | PFE GROSS % | ABBV GROSS % | PFE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $61.16B | 74.3% | 70.2% | $9.07B | $17.82B |
| FY 2024 | $63.63B | $56.33B | 71.9% | 70.0% | $9.84B | $17.83B |
| FY 2023 | $50.91B | $54.32B | 44.0% | 44.0% | $6.41B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
ABBV // BETA 1.15